Assertio Therapeutics (ASRT) stock price, revenue, and financials

Assertio Therapeutics market cap is $72.1 m, and annual revenue was $229.50 m in FY 2019

$72.1 M

ASRT Mkt cap, 23-Sept-2020

$20.9 M

Assertio Therapeutics Revenue Q1, 2020
Assertio Therapeutics Net income (Q1, 2020)41.2 M
Assertio Therapeutics EBIT (Q1, 2020)-16.6 M
Assertio Therapeutics Cash, 31-Mar-2020106 M
Assertio Therapeutics EV-33.5 M

Assertio Therapeutics Revenue

Assertio Therapeutics revenue was $229.50 m in FY, 2019

Embed Graph

Assertio Therapeutics Income Statement

Quarterly

USDQ2, 2011Q3, 2011Q1, 2012Q2, 2012Q3, 2012Q1, 2013Q2, 2013Q3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020

Revenue

16.2m9.2m2.1m3.2m9.7m9.1m30.0m37.5m76.5m67.7m51.5m32.2m94.5m104.9m104.8m116.7m110.5m90.4m100.5m95.4m128.4m63.3m77.5m57.9m57.2m55.1m20.9m

Cost of goods sold

2.1m1.2m518.0k1.4m1.8m1.5m1.7m1.8m3.7m4.7m3.5m3.1m22.9m20.9m23.5m21.0m20.2m17.8m19.7m17.4m12.0m2.8m3.0m2.6m2.1m2.2m

Gross profit

14.0m8.1m1.6m1.8m7.9m7.6m28.3m35.7m72.8m63.1m48.0m29.1m71.6m83.9m81.2m95.7m90.3m72.7m80.7m78.0m116.4m60.5m74.5m55.4m55.1m52.9m

Gross profit Margin, %

87%88%75%55%82%84%94%95%95%93%93%90%76%80%78%82%82%80%80%82%91%96%96%96%96%96%

Sales and marketing expense

11.1m6.0m

R&D expense

4.0m3.2m3.5m3.5m5.3m3.3m1.4m1.3m2.0m1.4m1.6m1.9m4.7m4.6m5.9m7.1m10.4m5.1m5.6m1.8m1.5m2.2m2.1m1.8m1.3m1.5m1.0m

General and administrative expense

21.0m21.5m21.8m25.0m26.8m26.0m25.4m26.4m32.5m32.6m27.1m34.5m57.4m49.1m52.6m51.9m51.6m48.5m50.0m48.9m29.0m31.3m33.4m25.0m24.8m36.1m27.3m

Operating expense total

20.0m17.4m10.5m17.7m9.5m13.2m27.7m28.9m37.1m36.5m31.3m38.9m88.9m80.7m85.5m86.1m89.0m79.3m84.8m76.8m65.0m64.7m64.9m52.3m51.5m63.0m28.4m

Depreciation and amortization

963.0k1.2m2.5m2.5m2.5m2.5m26.7m27.0m27.0m27.0m27.0m25.7m25.7m25.7m25.4m25.4m25.4m25.4m25.4m25.4m

EBIT

(6.0m)(9.3m)(8.9m)(16.0m)(1.5m)(5.5m)532.0k6.8m35.7m26.5m16.7m(9.8m)(17.2m)3.2m(4.3m)9.7m1.3m(6.7m)(4.1m)1.2m51.3m(4.2m)9.6m3.1m3.6m(10.1m)(16.6m)

EBIT margin, %

(37%)(101%)(424%)(499%)(16%)(61%)2%18%47%39%32%(31%)(18%)3%(4%)8%1%(7%)(4%)1%40%(7%)12%5%6%(18%)(80%)

Interest expense

39.0k24.0k204.0k39.0k116.0k6.0k258.0k6.0m5.5m6.3m6.0m22.0m22.6m22.6m25.9m20.2m19.9m22.8m17.7m17.8m16.9m45.5m11.7m

Investment income

357.0k410.0k143.0k204.0k96.0k70.0k46.0k27.0k27.0k20.0k23.0k57.0k61.0k62.0k130.0k67.0k113.0k250.0k282.0k72.0k229.0k67.0k677.0k

Pre tax profit

(5.7m)(8.9m)(8.8m)(15.8m)(1.5m)(5.6m)538.0k6.6m29.8m21.0m10.4m(15.8m)(39.2m)(19.3m)(26.9m)(16.2m)(18.9m)(26.5m)(26.9m)(16.5m)33.5m(21.2m)55.1m(14.1m)(12.5m)1.6m43.3m

Income tax expense

1.0k(348.0k)9.0k1.0k11.0k(99.0k)60.0k66.0k11.8m8.3m4.0m(4.2m)(17.6m)(7.6m)(6.0m)(5.7m)(6.0m)202.0k(249.0k)(513.0k)(325.0k)(120.0k)6.8m210.0k1.1m(1.7m)2.0m

Net Income

(5.7m)(8.6m)(8.8m)(15.8m)(1.5m)(5.5m)478.0k6.5m17.9m12.7m6.5m(11.6m)(21.7m)(11.8m)(20.9m)(10.5m)(12.9m)(26.7m)(26.7m)(16.0m)33.8m(21.0m)48.3m(14.3m)(13.6m)3.3m41.2m

Assertio Therapeutics Balance Sheet

Quarterly

USDQ2, 2011Q3, 2011Q1, 2012Q2, 2012Q3, 2012Q1, 2013Q2, 2013Q3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020

Cash

36.3m19.9m40.2m13.5m27.4m21.9m44.9m64.3m195.3m211.1m546.7m52.8m94.1m107.5m182.0m87.8m90.4m187.8m113.2m107.6m101.7m57.2m121.9m109.7m68.3m54.2m106.0m

Accounts Receivable

7.4m827.0k486.0k1.9m4.8m5.3m6.7m8.3m12.8m17.3m20.0m23.5m59.8m68.4m69.9m79.5m87.0m67.5m78.3m77.2m62.4m42.1m43.9m43.5m34.3m43.4m13.0m

Prepaid Expenses

2.9m5.5m5.1m6.3m2.7m5.6m6.0m6.1m21.8m7.0m6.8m8.4m19.8m20.5m12.3m15.7m11.9m12.5m13.1m17.7m23.8m22.7m57.3m25.7m26.2m23.5m10.7m

Inventories

5.0m3.3m6.6m8.0m7.8m8.7m7.2m7.8m8.5m7.8m7.3m6.5m10.4m11.4m10.9m10.4m11.3m12.0m10.4m10.4m5.4m5.0m4.3m3.1m3.0m3.3m518.0k

Current Assets

129.7m125.2m115.2m97.5m105.4m96.0m97.5m110.6m313.3m309.6m632.5m613.5m232.2m302.8m292.6m230.2m260.9m286.8m219.0m219.3m193.3m127.1m227.4m182.0m139.0m124.4m180.1m

PP&E

994.0k1.1m1.1m1.4m5.3m8.1m8.2m8.4m8.1m7.7m7.4m7.2m16.0m15.4m15.1m16.2m16.1m15.1m14.5m13.9m11.7m11.1m11.8m16.6m13.1m3.9m3.2m

Total Assets

181.3m171.8m152.0m143.1m144.9m135.2m134.0m156.7m468.7m458.5m742.4m704.4m1.3b1.4b1.3b1.2b1.2b1.2b1.1b1.1b1.0b912.2m983.5m883.5m812.9m756.9m219.3m

Accounts Payable

23.5m25.8m24.8m30.2m32.2m27.9m24.4m30.3m39.5m44.3m45.6m55.8m113.9m3.2m7.4m11.3m18.5m7.2m12.4m7.0m10.2m3.1m17.4m5.4m2.2m22.7m5.0m

Short-term debt

121.0k304.0k

Current Liabilities

32.1m34.2m35.7m40.3m42.9m32.1m28.0m34.1m119.3m114.6m116.0m61.7m135.7m180.2m309.1m217.9m216.0m301.5m278.9m263.2m257.1m231.8m261.1m223.0m176.9m205.7m122.3m

Long-term debt

226.8m233.1m236.3m239.6m241.0m244.9m248.7m256.8m260.9m265.2m273.9m278.5m283.1m292.6m297.6m190.9m

Total Debt

121.0k226.8m233.1m236.3m239.6m241.0m244.9m248.7m256.8m260.9m265.2m273.9m278.5m283.1m292.6m297.6m190.9m304.0k

Total Liabilities

721.0m741.1m674.9m615.4m508.4m135.2m

Common Stock

200.8m202.0m205.3m207.5m209.2m213.1m215.3m218.1m225.4m230.9m234.9m246.0m252.6m258.2m269.9m277.9m283.9m298.1m306.1m309.4m316.7m323.0m6.0k6.0k6.0k8.0k8.0k

Additional Paid-in Capital

1.1m1.9m75.5m78.0m79.1m80.8m78.8m78.7m79.2m75.9m75.7m75.7m75.1m74.9m400.9m405.4m407.9m455.6m442.6m

Retained Earnings

(75.2m)(83.7m)(106.4m)(122.2m)(123.7m)(132.8m)(132.4m)(125.8m)(66.1m)(53.4m)(46.9m)36.1m14.4m2.6m(48.9m)(59.5m)(72.4m)(143.8m)(170.4m)(186.4m)(185.7m)(206.7m)(158.5m)(196.9m)(210.5m)(207.2m)(358.6m)

Total Equity

125.8m118.2m99.0m85.4m85.6m80.3m82.9m92.2m160.3m179.3m263.5m360.1m346.1m341.7m299.7m297.1m290.7m230.2m211.4m198.6m206.1m191.2m242.4m208.5m197.4m248.4m84.0m

Financial Leverage

1.4 x1.5 x1.5 x1.7 x1.7 x1.7 x1.6 x1.7 x2.9 x2.6 x2.8 x2 x3.8 x4 x4.5 x4.2 x4.3 x5.1 x5.1 x5.3 x4.9 x4.8 x4.1 x4.2 x4.1 x3 x2.6 x

Assertio Therapeutics Cash Flow

Quarterly

USDQ2, 2011Q3, 2011Q1, 2012Q2, 2012Q3, 2012Q1, 2013Q2, 2013Q3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020

Net Income

93.1m84.6m(8.8m)(24.6m)(26.1m)(5.5m)(5.0m)1.5m17.9m30.7m37.1m(11.6m)(33.3m)(45.1m)(20.9m)(31.5m)(44.4m)(26.7m)(53.4m)(69.4m)33.8m12.8m61.0m(14.3m)(27.9m)(24.6m)41.2m

Depreciation and Amortization

123.0k232.0k238.0k320.0k1.4m1.3m2.6m4.1m3.0m6.1m9.1m3.0m30.3m57.9m27.7m55.3m83.0m26.3m52.7m79.0m26.9m53.8m80.7m26.0m51.5m77.2m8.1m

Accounts Receivable

(1.6m)(1.1m)1.9m1.7m(2.3m)(1.6m)(1.1m)(2.4m)(3.4m)2.6m(1.1m)3.6m(32.7m)(41.4m)1.2m(8.4m)(15.8m)34.5m23.7m24.9m10.1m30.3m28.6m(6.3m)2.9m(6.2m)29.8m

Inventories

(3.4m)(1.7m)(1.2m)(902.0k)(667.0k)844.0k2.2m2.9m1.7m2.4m2.9m1.6m9.2m7.5m(761.0k)(346.0k)(1.5m)873.0k490.0k272.0k7.5m7.8m8.5m(40.0k)195.0k(213.0k)(2.4m)

Accounts Payable

4.1m6.9m(729.0k)2.5m2.3m316.0k

Cash From Operating Activities

82.1m72.4m(11.5m)(24.9m)(25.3m)(4.9m)(3.7m)10.4m(65.3m)(58.4m)(59.1m)(2.5m)37.1m85.8m(16.5m)11.5m27.9m16.0m38.1m34.9m(27.0m)(14.0m)56.7m27.2m48.7m82.6m(25.1m)

Purchases of PP&E

(444.0k)(665.0k)(134.0k)(502.0k)(2.1m)(461.0k)(1.1m)(1.4m)(660.0k)(783.0k)(853.0k)(342.0k)(1.1m)(1.2m)(45.0k)(2.5m)(2.8m)(470.0k)(504.0k)(563.0k)(1.0k)(772.0k)(4.0m)(13.0k)(621.0k)(1.5m)(9.0k)

Cash From Investing Activities

(73.8m)(80.6m)27.2m12.9m26.7m(2.7m)18.5m22.5m12.8m17.8m17.3m(437.8m)(1.0b)(1.0b)95.8m74.6m58.6m52.4m55.7m53.3m1.4m653.0k(5.6m)(13.0k)(7.7m)(1.5m)449.0m

Long-term Borrowings

(2.1m)(2.2m)

Cash From Financing Activities

5.5m5.6m468.0k1.4m1.9m408.0k1.1m2.3m3.1m7.1m343.8m4.4m570.5m573.8m1.6m(99.4m)(97.2m)1.7m(98.3m)(98.4m)360.0k(56.3m)(56.2m)(28.4m)(83.6m)(137.9m)(360.1m)

Net Change in Cash

13.8m(2.6m)16.2m(10.5m)3.3m(7.1m)15.9m35.2m(49.4m)(33.5m)302.0m(435.9m)(394.6m)(381.2m)80.9m(13.3m)(10.7m)70.1m(4.5m)(10.1m)(25.2m)(69.7m)(5.0m)(1.3m)(42.6m)(56.8m)63.9m

Interest Paid

4.1m4.1m23.7m20.1m35.8m53.0m17.4m30.2m44.8m14.7m25.1m38.8m13.2m21.6m32.1m10.8m

Income Taxes Paid

(600.0k)40.0k77.0k78.0k83.0k121.0k121.0k1.0k166.0k4.9m420.0k420.0k100.0k

Assertio Therapeutics Ratios

USDQ2, 2011

Financial Leverage

1.4 x

Assertio Therapeutics Employee Rating

3.98 votes
Culture & Values
4.4
Work/Life Balance
4.4
Senior Management
4
Salary & Benefits
3.4
Career Opportunities
3
Source